Global Partners LP GLP
44.30 USD +0.83 (+1.91%)
Regular-session close
44.74 +0.44 +0.99%
Pre-market · Nov 16, 7:00 AM ET
42.48 Day range 45.00
39.58 52-week range 54.29
- YTD
- +5.85%
- 1 year
- +4.58%
News
nypost.com CVS says GLP-1s save money when priced below $350 per month The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to…
zacks.com Global Partners (GLP) Moves to Strong Buy: Rationale Behind the Upgrade Global Partners (GLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Best Value Stocks to Buy for November 12th PANL, GLP, and LRN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 12, 2026.
zacks.com Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock? NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
fxempire.com Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
seekingalpha.com Hims & Hers Health: Don't Nitpick Quarterly Results Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly…
fool.com Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change…
globenewswire.com Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration Highlights Conexeu has launched a human collagen initiative at its Vancouver research and development facility, for its aesthetics program, focused on potential tissue-restoration applications…
globenewswire.com Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that…
cnbc.com FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of…
247wallst.com Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill Eli Lilly (NYSE:LLY | LLY Price Prediction) just gave its newest drug a second act.
247wallst.com Global Partners Yields 7.15%. Is Its Dividend Safe? Twenty straight quarterly raises sound reassuring, but a wholesale margin windfall and softening retail demand are pulling in opposite directions at Global Partners. Which of those forces will decide…
zacks.com Here's Why Global Partners (GLP) Is a Great 'Buy the Bottom' Stock Now Global Partners (GLP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could…
globenewswire.com Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in…
benzinga.com Global Partners Q3 2026 Earnings Call Transcript Global Partners (NYSE:GLP) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by…benzinga.com Global Partners Q3 EPS $1.26 Misses $1.61 Estimate, Sales $6.684B Miss $7.412B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $1.26 per share which missed the analyst consensus estimate of $1.61 by 21.74 percent. This is a 90.91 percent increase over earnings of…
